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B cell expansion, even in the absence of a complete B cell
depletion in the BM. This observation may be relevant when
considering the biological effects of B cell depletion in other
B cell related autoimmune diseases, such as systemic lupus
erythaematosus (SLE),6 Sjo¨gren syndrome7 or rheumatoid
arthritis (RA),8 where a polyclonal expansion is a key
pathological feature and qualitative biological effects may be
more difficult to be disclosed by molecular studies. Notably,
recent data demonstrate changes in the B cell repertoire at the
time of B cell reconstitution after rituximab treatment for RA9
and SLE10 by immunophenotyping of peripheral blood B cells,
consistent with the qualitative effects on BM proliferation
herein reported in MC.
In conclusion, changes in the molecular pattern of BM B cell
clonal expansion after rituximab therapy further support the
role of peculiar B cell clones in the pathogenesis of nephritis in
MC, and highlight qualitative rather than quantitative effects of
B cell depletion therapy in this disease.
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On the applicability of the CASPAR
criteria in psoriatic arthritis
While conducting a cross-sectional, population based twin
study on psoriatic arthritis (PsA),1 we concurrently adopted
the items required for the classification of PsA according to the
Moll and Wright (M&W) definition,2 the Vasey and Espinoza
(V&E) criteria3 and the CASPAR criteria.4 The study was based
on questionnaire surveys to all Danish twins. This method
identified 228 twins with self-reported PsA. After subsequent
invitation, 164 twins participated in the diagnostic validation
that included telephone interview, scrutiny of medical files,
structured interview, clinical examination and serological tests
for rheumatoid factor.
Surprisingly, the highest PsA prevalence was recorded using
the M&W and not the other criteria: M&W = 54/34 944
(0.15%), V&E = 42/34 944 (0.12%) and CASPAR = 50/34 944
(0.14%). The single most important reason for missing
Table 1 Clinical, laboratory and histopathological features at baseline evaluation
Patient 1 Patient 2 Patient 3
Gender Female Female Male
Age, years 58 62 50
HCV genotype 1b 1b 3
Cryoglobulins, mg/dl 3550 2993 324
Rheumatoid factor, IU/litre 418 3710 86
C4, mg/dl (normal range: 10–
40 mg/dl)
2 12 12
Other clinical manifestations
besides nephritis
Peripheral neuropathy,
purpura, fever
Peripheral neuropathy Peripheral neuropathy
Bone marrow biopsy Reactive lymphoproliferation Normal Reactive lymphoproliferation
Duration of nephritis, months 18 19 36
Renal biopsy pre-rituximab Not performed Membranoproliferative
glomerulonephritis
Membranoproliferative
glomerulonephritis
GFR, ml/min 22.7 57.8 42.0
Creatinine, mg/dl 2.3 0.9 2.3
Proteinuria, mg/24 h 2204 1500 4500
Urinary sediment Active Active Active
GFR, glomerular filtration rate; HCV, hepatitis C virus.
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classification by the V&E or the CASPAR criteria was that a
diagnosis of psoriasis by a rheumatologist or a dermatologist in
the past is weighted lower than a diagnosis made at the current
clinical examination when these instruments are used. Since
many epidemiological studies have a cross-sectional design and
hence include examination of cases at one time point only, with
or without additional scrutiny of medical files, and because
psoriatic skin and joint disease have a remitting–relapsing
course and may eventually enter a complete remission, it would
seem plausible not only to accept a previous diagnosis of
arthritis by a rheumatologist but also to include psoriatic skin
disease in the past documented by a dermatologist or a
rheumatologist. To improve the utility of the CASPAR criteria
in the present era of expanding use of highly effective biological
agents, we therefore propose that the CASPAR criteria are
modified accordingly (box 1). We acknowledge that this
modification of the CASPAR needs further validation.
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Box 1 Modified CASPAR criteria (proposed modifications
in italics)
To meet the CASPAR (Classification criteria for Psoriatic
ARthritis) criteria, a patient must have inflammatory articular
disease (joint, spine or enthesal) at current examination or
previously documented by a rheumatologist with >3 points from
the following five categories:
1. Definite psoriasis or a personal history of psoriasis or a
family history of psoriasis*
– Definite psoriasis defined as psoriatic skin or scalp
disease present at current examination or previously
documented by a rheumatologist or dermatologist
(assigned a score of 2).
– A personal history of psoriasis is defined as a history of
psoriasis obtained from the patient (assigned a score of 1).
– A family history of psoriasis is defined as a history of
psoriasis in a first- or second-degree relative according to
patient report (assigned a score of 1).
2. Typical psoriatic nail dystrophy including onycholysis,
pitting and hyperkeratosis observed on current physical
examination or documented by a rheumatologist or
dermatologist (assigned a score of 1).
3. A negative test result for the presence of rheumatoid factor
by any method except latex but preferably by enzyme-linked
immunosorbent assay or nephelometry, according to the
local laboratory reference range (assigned a score of 1).
4. Either current dactylitis, defined as swelling of an entire
digit, or a history of dactylitis recorded by a rheumatologist
(assigned a score of 1).
5. Radiographic evidence of juxta-articular new bone
formation, appearing as ill-defined ossification near joint
margins (but excluding osteophyte formation) on plain
radiographs of the hand or foot (assigned a score of 1).
*A personal history of psoriasis is only included in the score if
definite psoriasis is not documented. A family history of psoriasis
is only included in the score if neither definite psoriasis nor a
personal history of psoriasis is present.
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